As of January 22, 2025, Viridian Therapeutics (VRDN) has a market cap of $1.45 billion USD. According to our data, Viridian Therapeutics is ranked No.4638 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $1.45 B |
-4.28%
|
Dec 31, 2024 | $1.52 B |
-11.98%
|
Dec 29, 2023 | $1.73 B |
-25.44%
|
Dec 30, 2022 | $2.31 B |
47.75%
|
Dec 31, 2021 | $1.57 B |
20.18%
|
Dec 31, 2020 | $1.30 B |
128.47%
|
Dec 31, 2019 | $0.57 B |
-84.16%
|
Dec 31, 2018 | $3.60 B |
-70.95%
|
Dec 29, 2017 | $12.39 B |
108.18%
|
Dec 30, 2016 | $5.95 B |
-55.35%
|
Dec 31, 2015 | $13.33 B |
-70.55%
|
Dec 31, 2014 | $45.27 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Regeneron Pharmaceuticals
REGN
|
$74.73 B |
1.236 B
|
USA
|
Bristol-Myers Squibb
BMY
|
$115.79 B |
-0.003 M
|
USA
|
Amgen
AMGN
|
$146.98 B |
0.004 M
|
USA
|
AbbVie
ABBV
|
$299.00 B |
-0.007 M
|
USA
|
Eli Lilly
LLY
|
$678.07 B |
0.022 M
|
USA
|
Gilead Sciences
GILD
|
$115.95 B |
0.002 M
|
USA
|
Biogen
BIIB
|
$20.80 B |
0.000 M
|
USA
|
Novartis
NVS
|
$196.27 B |
-0.007 M
|
Switzerland
|
Merck
MRK
|
$242.04 B |
-0.000 M
|
USA
|
Sanofi
SNY
|
$129.14 B |
0.001 M
|
France
|
Alnylam Pharmaceuticals
ALNY
|
$34.38 B |
-0.000 M
|
USA
|
Market Cap | = | VRDN Stock Price | * | VRDN Shares Outstanding |
= | $18.35 | * | 79.21 M | |
= | $1.45 B |